JAMA Pediatrics reports elevated biliary event risk in youth on GLP-1 drugs

Researchers writing in JAMA Pediatrics report that young people taking GLP-1 receptor agonists face a two- to threefold higher risk of gallbladder problems compared with similar young people not taking the drugs ^[1]. The letter, from a team including Josélio Rodrigues de Oliveira Filho of Mass General Brigham and Harvard Medical School, is one of the first large studies to look specifically at biliary risk in patients aged 12 to 21 ^[1].

The researchers used the TriNetX health records network to find 18,759 patients ages 12 to 21 who were diagnosed with overweight or obesity between January 2022 and May 2026 and treated with a GLP-1 receptor agonist ^[1]. They matched each of these patients to a similar patient who was not on the drugs, using age, sex, and other health conditions. The GLP-1 group averaged 17.4 years old and was 63% girls; the comparison group averaged 17.5 years old and was 64% girls ^[1]. Patients on the drugs were followed for a median of 364 days, while the comparison group was followed for a median of 849 days ^[1].

In the main analysis, teens on GLP-1 drugs were more likely to have biliary colic, a type of gallbladder pain, and more likely to have their gallbladder removed, with risk ratios of 1.62 and 1.39 ^[1]. A more detailed time-based analysis found even larger gaps: the hazard ratio was 2.22 for cholecystitis, or gallbladder inflammation, 2.92 for biliary colic, and 2.39 for gallbladder removal ^[1].

The pattern held up in a subgroup of 8,046 patients with class I or II obesity, followed for a median of 387 days compared with 903 days for their matched nonusers ^[1]. In this narrower group, the time-based analysis found hazard ratios of 3.36 for cholecystitis, 2.78 for biliary colic, and 2.93 for gallbladder removal ^[1]. The researchers said there were too few events among patients with overweight or class III obesity to draw firm conclusions for those groups ^[1].

The authors wrote that the biliary risk "likely reflects rapid weight loss, which predisposes to gallstone formation in children with obesity, compounded by GLP-1 [receptor agonist]–mediated gallbladder dysmotility," adding that "adult data suggest a pharmacologic mechanism" ^[1]. They also cautioned that this was an observational study: "Causality cannot be established, and residual confounding cannot be excluded" ^[1].

Why it matters for patients

Gallbladder disease is already listed as a known risk of GLP-1 drugs in adults, but data in people under 21 have been limited even as prescribing to minors has grown ^[1]. This study adds some of the first large-scale pediatric evidence, and the size of the risk increase — roughly two to three times higher across several measures — echoes what has been seen in adults ^[1].

For families and clinicians managing pediatric obesity treatment, the findings underscore that biliary symptoms such as abdominal pain, especially after fatty meals, are a known possibility during GLP-1 treatment in this age group, not just in adults ^[1]. The study does not establish that the drugs directly cause gallbladder disease in every case, since factors like rapid weight loss itself can raise gallstone risk independent of the medication ^[1].

What happens next

The study's authors called for more research, saying "prospective studies should clarify risk stratification, evaluate whether prophylactic strategies used in bariatric populations could be applied, and identify whether monitoring protocols can reduce biliary morbidity" ^[1]. They also recommended "vigilance for biliary symptoms" when prescribing these drugs to young people, though the letter stops short of proposing specific screening or monitoring rules ^[1]. No regulatory action or label change for pediatric use is mentioned in the available reporting.